<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-like weak inducer of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> (TWEAK) has been implicated in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> development and progression </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this study was to investigate the role of TWEAK in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) progression </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: To investigate the involvement of TWEAK in the progression of human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, <z:mpath ids='MPATH_458'>normal</z:mpath>, and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> specimens from 174 patients were analyzed immunohistochemically for the expression of TWEAK </plain></SENT>
<SENT sid="3" pm="."><plain>TWEAK recombinant protein treatment, transfection of expression plasmids, and small interfering <z:chebi fb="40" ids="33697">RNA</z:chebi> to knockdown TWEAK expression were performed to test invasive ability with a Boyden chamber </plain></SENT>
<SENT sid="4" pm="."><plain>The <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression profile in recombinant TWEAK treatment was compared to a control group by microarray analysis </plain></SENT>
<SENT sid="5" pm="."><plain>To identify downstream effectors, Raf kinase inhibitor (RKIP) and its correlation with TWEAK in vitro and in vivo were examined by quantitative real-time polymerase chain reaction and invasion assays </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients whose <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> displayed high TWEAK expression had a statistically significantly higher overall survival and a disease-free advantage over those with a low TWEAK expression </plain></SENT>
<SENT sid="7" pm="."><plain>In in vitro invasion assays, alterations in TWEAK expression in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines inversely modulated their invasive ability </plain></SENT>
<SENT sid="8" pm="."><plain>By means of integrated genomics, we identified RKIP as a downstream effector in TWEAK-mediated invasion inhibition </plain></SENT>
<SENT sid="9" pm="."><plain>Knockout of RKIP expression in HCT116 cells by short hairpin <z:chebi fb="40" ids="33697">RNA</z:chebi> (shRKIP) resulted in increased invasiveness </plain></SENT>
<SENT sid="10" pm="."><plain>Clinically, RKIP and TWEAK <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression showed strong positive correlations in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patient samples </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Our results implicate TWEAK as a key regulator of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> invasion, and it appears to be a useful prognostic factor for patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>